- Home
- SLN vs PSF Comparison
SLN vs PSF Comparison
Compare SLN & PSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- PSF
- Stock Information
- Founded
- SLN 1994
- PSF 2010
- Country
- SLN United Kingdom
- PSF United States
- Employees
- SLN N/A
- PSF N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- PSF Investment Managers
- Sector
- SLN Health Care
- PSF Finance
- Exchange
- SLN Nasdaq
- PSF Nasdaq
- Market Cap
- SLN 299.4M
- PSF 245.5M
- IPO Year
- SLN N/A
- PSF N/A
- Fundamental
- Price
- SLN $4.81
- PSF $20.40
- Analyst Decision
- SLN Buy
- PSF
- Analyst Count
- SLN 5
- PSF 0
- Target Price
- SLN $32.60
- PSF N/A
- AVG Volume (30 Days)
- SLN 60.5K
- PSF 25.0K
- Earning Date
- SLN 08-07-2025
- PSF 01-01-0001
- Dividend Yield
- SLN N/A
- PSF 7.69%
- EPS Growth
- SLN N/A
- PSF N/A
- EPS
- SLN N/A
- PSF N/A
- Revenue
- SLN $27,169,000.00
- PSF N/A
- Revenue This Year
- SLN N/A
- PSF N/A
- Revenue Next Year
- SLN N/A
- PSF N/A
- P/E Ratio
- SLN N/A
- PSF N/A
- Revenue Growth
- SLN 22.28
- PSF N/A
- 52 Week Low
- SLN $1.97
- PSF $16.00
- 52 Week High
- SLN $20.48
- PSF $20.19
- Technical
- Relative Strength Index (RSI)
- SLN 34.88
- PSF 52.67
- Support Level
- SLN $4.91
- PSF $20.36
- Resistance Level
- SLN $5.34
- PSF $20.50
- Average True Range (ATR)
- SLN 0.48
- PSF 0.15
- MACD
- SLN -0.05
- PSF -0.02
- Stochastic Oscillator
- SLN 0.71
- PSF 47.37
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.